Yuhan, JW Pharmaceutical, GC Biopharma, and Hanmi strengthen roles across the drug value chain.
Milestone income, rare-disease assets, CDMO alliances, and platform patents underpin new growth.
A visual representation of Korean pharma’s global value chain, from R&D labs to large-scale biologics manufacturing and IP strategy meetings. AI-generated illustration created with Perplexity, powered by GPT-5.1
Yuhan announced it had reached a commercialization milestone with its global partner for lazertinib, sold in Korea as Leclaza. The payment relates to preparations for the European launch of the EGFR-targeted lung cancer therapy. The company expects more milestones and royalties as the product expands in major markets.
JW Pharmaceutical reported non-clinical data for a novel therapy targeting rare pediatric brain diseases at a global orphan drug conference. The candidate targets conditions with few or no approved treatments, reflecting the industry's growing focus on rare and pediatric indications. The company plans to use the data to advance clinical development and seek global partners.
GC Biopharma signed a memorandum of understanding with Merck to cooperate on biopharmaceutical manufacturing. The companies will work together on process optimization, raw-material solutions, and other technologies to support large-scale biologics production. GC Biopharma views the deal as a way to boost its competitiveness as a global CDMO player.
Hanmi Science highlighted that it holds key patents for Hanmi Pharm’s proprietary “LAPSCOVERY” long-acting platform and other core technologies. The group aims to build a more stable revenue base by expanding license deals and IP-based income from these platforms. A company official said Hanmi will continue focusing on strengthening its patent portfolio to support global partnerships and long-term growth.
By Min Byung-kwun, Park Sung-jae
kdf＠kdfnews.com
댓글
0